Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire Kuwait.
Press releases published on June 30, 2025
Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Denali sur NCX 470
GlobeNewswire
·
June 30, 2025
30 Juin 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui que le dernier patient a terminé l’essai …
Press release: Availability of the Q2 2025 Aide mémoire
GlobeNewswire
·
June 30, 2025
Availability of the Q2 2025 Aide mémoire Paris, France – June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: Second quarter 2025 (sanofi.com) As for each quarter, Sanofi …
Communiqué de presse : Mise en ligne du document «Q2 2025 Aide mémoire »
GlobeNewswire
·
June 30, 2025
Mise en ligne du document «Q2 2025 Aide mémoire » Paris, France, le 30 juin 2025. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q2 2025 Aide mémoire ». Résultats du deuxième trimestre …
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
GlobeNewswire
·
June 30, 2025
Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatment Japanese Ministry of …
Communiqué de presse : Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique
GlobeNewswire
·
June 30, 2025
Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique Deux études de phase 3 sont actuellement en cours pour tester le riliprubart chez les personnes atteintes de PIDC comme …
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
GlobeNewswire
·
June 30, 2025
Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong …
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
GlobeNewswire
·
June 30, 2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological …
Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs
GlobeNewswire
·
June 30, 2025
Press Release Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs Geneva, Switzerland – June 30, 2025 – STALICLA SA, a Geneva-based clinical-stage biotech company pioneering …